Celecoxib × Other hematologic neoplasm × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
NCT00093678 2015-10-08

Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer

Eastern Cooperative Oncology Group

Phase NA Withdrawn